Lilly Tightens Its Diabetes Grip. Onswik Seals It.
With FDA clearance of a once-weekly insulin, Lilly now pairs GLP-1s, basal insulin, and an oral pill in one unmatched lineup.
ConocoPhillips Doubled Its Adjusted EPS. Q3 Is Nov. 5.
The largest independent E&P is returning 45% of cash flow.
Qualcomm Is Worth More Than the Market Thinks
Apple will keep paying royalties even as it builds its own modems. That distinction, combined with a new Snapdragon platform, is not yet priced in.
Two Data Releases This Morning Could Decide Stocks’ Open
Durable goods at 8:30, final Michigan sentiment at 10:00: what it means for XLY, XLP, and SPY with markets pricing a 65% October hike chance.
Brent at $106.60 Cuts Both Ways. Here Is How to Stay Long Energy Without Getting Caught Offside.
The Hormuz deal headline that pared crude’s $108 spike also revealed exactly which energy names survive a reopening and which do not.
BlackRock Owns the Plumbing of Tokenized Finance Now
With $15.3 trillion in AUM and a $400 billion private markets target, BLK is not just riding the tokenization wave — it is building the pipes everyone else must use.
The $349 Ray-Ban Is Now Meta’s Real Bet
Meta’s audio-only Ray-Bans ship Oct. 13. They matter more to Reality Labs today than the $1,300 VR glasses due in spring 2027.
Royal Caribbean Is Paying $3 Billion for Half of Sandals. Investors Have Questions.
The market’s immediate verdict is a rebuke of CEO Jason Liberty’s capital allocation at the worst possible moment.
Shopify’s 7% Rally Reveals the Real Battle: Who Owns the Agentic Checkout?
Amazon is building a wall around its customers. Shopify is renting its rails to everyone. One of these strategies compounds for a decade.
AMD, Arm, and Intel Reset the AI Trade
When server processors surge past Nvidia in one session, investors have to ask whether GPUs are still the scarce asset.